Genentech’s Hillsboro Oregon campus—Hillsboro Innovative Therapies (HIT)—serves as a critical hub for emerging cell & gene therapy manufacturing. Housed within a modern 75-acre facility just outside Portland, HIT is at the forefront of advancing cell and gene therapy medicines through accelerated clinical and commercial manufacturing capabilities, aligning with Genentech’s mission to bring transformative therapies to patients. As part of Genentech’s Cell and Gene Therapy community, this role offers the opportunity to shape and scale advanced therapy platforms through cross-site collaboration, data-driven innovation, and continuous improvement. This leader will play a pivotal role in defining and executing the MSAT strategy for cell therapy, guiding decisions, influencing global technology platforms, and representing HIT in strategic Roche network initiatives.